Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension.

Next Previous
X
Search
Trial Profile

An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
  • Indications Essential hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 12 Jun 2012 Actual patient number changed from 944 to 1342 as reported by ClincialTrials.gov (Parent trial: NCT01237223).
    • 25 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov (NCT01237223).
    • 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT01237223).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top